Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... -year cumulative increase in drug costs (RUB 1,008 million) will be offset by a decrease in non-drug ..."
 
Vol 8, No 1 (2015) BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... in the first line of therapy of a multiple myeloma for patients more senior 65 years old with clinical ..."
 
Vol 7, No 2 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin
"... years old with clinical manifestations of a polineuropathy, which autological transplantation of stem ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... improvement from the perspective of quality adjusted life-years. Simultaneously liraglutide demonstrates ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... the cost rate to 289 199 RUB in 10 years. ..."
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... spending starting from the first year; the total five-year budget savings are 275 RUB millions.  ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... эффективности, в качестве критериев эффективности были использованы значения добавленных лет жизни (LYG) и ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... at the same time constitute 5 213 900 000 rub. (670.5 to 1184.3 million rubles per year). Calculated unit ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment Abstract  similar documents
A. U. Kulikov, V. V. Babiy
"... year. Diabetes treatment schemes mostly focused on normalizing the blood glucose level. To achieve ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... , myorelaxants, physical therapy). Measured direct costs at 1-year follow-up. Quality of life was measured ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... of BV in patients with relapsed or refractory CD30-positive HL. Time horizon of the model was 40 years ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... year respectively, administration of Lacosamide as concomitant drug, in comparison with standard ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... and gender groups, as well as the volume of government spending. The cost of disability-adjusted life-year ..."
 
Vol 11, No 4 (2018) International experience in determining the cost-effectiveness thresholds Abstract  similar documents
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky
"... , which is represented by quality-adjusted life year (QALY) in most counties. However,PolandandBrazilallow ..."
 
Vol 9, No 1 (2016) SYSTEMATIC REVIEW OF PENTAGLOBIN EFFICACY IN PREVENTING MORTALITY IN NEWBORNS AND OLDER CHILDREN WITH BACTERIAL INFECTIONS AND SEPSIS Abstract  similar documents
V. K. Fedyaeva, O. Yu. Rebrova
"... от любых причин при бактериальных инфекциях и сепсисе у детей до двух лет Федяева В.К.1, Реброва ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... that dapagliflozin introduction could delay the start of insulin treatment by an average of 6.5 years that in turn ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... will be 69,305 million RUB/year, taking into account the accepted assumptions. Under the assumption of equal ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT Abstract  similar documents
N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova
"... , травматические, постинфекционные, опухолевые и др.) [9,19]. При СЛГ случаются судорожные приступы тонического ..."
 
Vol 9, No 3 (2016) HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE Abstract  similar documents
A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
"...  criteria of RA treatment were: patient-years in remission and patient-years in low disease activity. We ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... % and 7% for the first, second and third year is expected to result in cost savings of 26.4 million rubles ..."
 
Vol 8, No 2 (2015) CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA Abstract  similar documents
Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova
"... улучшение следующих показателей: ОФВ1, уменьшение дневных и ночных приступов удушья, количества обострений ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... with the same efficacy. Budgetary spending is decreased by 1.68 bln. rubles over 5 years with a gradual increase ..."
 
Vol 7, No 3 (2014) ECONOMIC JUSTIFICATION FOR TELEHEALTH TECHNOLOGY USE FOR PREVENTIVE MEDICAL EXAMINATION OF THE POPULATION IN REMOTE REGIONS Abstract  similar documents
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky
"... than one and a half years to coverage increase by medical care of the handicapped and removed ..."
 
Vol 7, No 4 (2014) IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? Abstract  similar documents
V. V. Omelyanovskiy
"... in Russia for several years already, while national or internal reference pricing system hasn’t been applied ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... caused with the studied diseases and the number of lost Disability Adjusted Life Years (DALY ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION Abstract  similar documents
A. Yu. Kulikov, I. Yu. Zinchuk
"... to placebo at 22311 RUB and 21345 RUB, respectively. Cost effectiveness analysis, based on the clinical ..."
 
Vol 11, No 3 (2018) Use of medications in children hospitalized with community-acquired pneumonia Abstract  similar documents
D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova
"... of this retrospective study (N = 547) showed that children aged 1 to 3 years were most vulnerable (31.44%). Along ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... included 2259 patient’s data files. The age of patients ranged from 0 to 18 years old. «Cost-effectiveness ..."
 
Vol 7, No 2 (2014) MANAGEMENT OF MAGNESIUM DEFICIENCY IN PREGNANT WOMEN: PHARMACOEPIDEMIOLOGIC STUDY Abstract  similar documents
D. V. Blinov, U. V. Zimovina, E. M. Dzhobava
"... . Materials and Methods: pregnant women (at any trimester) aged over 18 years were included. Mg deficiencies ..."
 
Vol 8, No 2 (2015) CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER Abstract  similar documents
Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov
"... venous port systems installed in 2262 for children between the ages of 2 months up to 17 years ..."
 
Vol 7, No 3 (2014) PHARMACOEPIDEMIOLOGY OF ORIGINAL DROTAVERINE USE IN DYSMENORRHEA: RESULTS OF AN INTERNATIONAL MULTICENTER STUDY Abstract  similar documents
A. L. Unanyan, V. A. Alimov, S. E. Arakelov, M. S. Afanasyev, D. V. Baburin, D. V. Blinov, T. D. Guriyev, U. V. Zimovina, A. E. Kadyrova, Yu. M. Kossovich, L. S. Polonskaya
"... .5 years. 86 % were females. Most suffered from dysmenorrhea (53%). They received drotaverine for 5.7±4 ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... ) per a year of saved life with consideration of its quality comprised 1,097,078 rubles without ..."
 
Vol 12, No 1 (2019) Efficacy of photodynamic therapy in treatment of adult patients with skin cancer Abstract  similar documents
O. V. Kirsanova
"... cancer in patients over 18 years old. To that end, we screened the PubMed database of medical ..."
 
Vol 5, No 3 (2012) CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE Abstract  similar documents
E. E. Arinina, M. A. Rashyd
"... was 1 year. Additional costs for insulin transition (Protaphane® /Actrapid® to Levemir® /NovoRapid ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... of type 2 DM complications in 5 years in patient with predefined risk factors. Among comparing strategies ..."
 
Vol 11, No 3 (2018) Economic barriers restraining the production of therapeutic recombinant human trypsin. Use of innovative technologies to overcome them Abstract  similar documents
S. V. Ponomarenko
"... pancreas has been used for over 80 years in the enzyme therapy in various diseases. Genetically engineered ..."
 
Vol 11, No 4 (2018) Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease Abstract  similar documents
V. I. Ignatyeva, S. V. Moiseev, N. M. Bulanov, E. A. Karovajkina, A S. Moiseev
"... years reduces the number of serious cardiovascular and renal complications by 25%. An early start of ERT ..."
 
Vol 5, No 2 (2012) PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS Abstract  similar documents
A. Yu. Kulikov, V. G. Serpikov
"... пациента за пять лет (при коэффициенте дисконтирования 3%), демонстрируя предпочтительность с точки зрения ..."
 
Vol 9, No 1 (2016) REVIEW OF HEALTH SYSTEM ORGANIZATION APPROACHES TO ESTIMATING SERVICE LEVELS AND EXPENDITURES FOR INPATIENT CARE SERVICES Abstract  similar documents
K. V. Gerasimova, D. V. Fedyaev, M. V. Sura, A. A. Tikhonova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... of previous years. Approaches to planning are typically part of political decision-making, developed ..."
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... by 120 million rubles over 5 years. The sensitivity analysis shows the results are robust ..."
 
Vol 12, No 2 (2019) Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available Abstract  similar documents
F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev
"... in the prices of the reference drugs that circulate together with generics/biosimilars for at least 4 years ..."
 
Vol 10, No 1 (2017) EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... impact and the “cost-effectiveness” parameters were analyzed using the MS Excel-model based on a 3-year ..."
 
Vol 10, No 4 (2017) PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... is about 58,710 per year, and the number of potentially targeted joints – 3,409 in adults; the figures ..."
 
Vol 6, No 2 (2013) PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION Abstract  similar documents
V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina
"... related to the virus. Use of ART allows to optimize the costs, the value of quality-adjusted life year ..."
 
Vol 7, No 2 (2014) EPIDEMIOLOGIC RESEARCH ON EPILEPSY IN MINSK Abstract  similar documents
T. V. Dokukina, T. S. Golubeva, I. V. Matveichuk, M. V. Mahrov, V. M. Loseva, E. V. Krupenkina, S. A. Marchuk
"... , перенесшего, по крайней мере, один эпилептический приступ за последние 5 лет, вне зависимости от применяемой ..."
 
Vol 9, No 2 (2016) EVALUATION OF RATIONALITY OF EXPENSES ON TREATMENT OF SEVERE COMMUNITY-ACQUIRES PNEUMONIA IN MULTI-PROFILE HOSPITAL Abstract  similar documents
I. V. Demko, N. V. Gordeeva, E. N. Bochanova, N. I. Golovina, A. Yu. Kraposhina, I. A. Soloveva, E. A. Sobko, T. V. Gaygolnik, S. V. Chubarova
"... hospital. Results. Expenses on the treatment of severe community-acquires pneumonia according to 2014 year ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... . Treatment with Tasigna compared with Gleevec characterizes as dominant according to used 1-year time ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET Abstract  similar documents
R. I. Yagudina, V. G. Serpik
"... weeks of the first year of treatment for a combination of Mimpara, vitamin E and drugs phosphorbinders ..."
 
Vol 11, No 1 (2018) CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation Abstract  similar documents
A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin
"... remains cost-effective even if the genotyping costs more than 3893.8 RUB  (199% of the current value ..."
 
Vol 10, No 2 (2017) ECONOMIC ASSESSMENT OF THE EFFECTIVENESS AND SAFETY OF THE COMMONLY PRACTICED PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS (BASED ON AN EARLIER EPIDEMIOLOGICAL SURVEY OF MULTIDISCIPLINARY HOSPITALS) Abstract  similar documents
Yu. M. Gomon, A. S. Kolbin, S. V. Sidorenko, A. M. Kuzhel’, A. V. Repina, Yu. V. Lobzin, Yu. E. Balykina
"... practice (RUB 4913,67 and 17837,71 respectively). The present analysis demonstrates that the PAP ..."
 
1 - 50 of 141 Items 1 2 3 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)